NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
Clinical Trials
66 trialsNCT07318805 2026-04-20
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Phase 1 Recruiting
NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT05579366 2026-04-07
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT04158258 2026-03-24
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT06271837 2025-10-22
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
AstraZeneca
Phase 2 Recruiting
NCT06769425 2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT05792410 2023-03-31
A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT03462251 2023-01-19
RIBBIT
iOMEDICO AG
Phase 3 Completed
NCT00773695 2023-01-09
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00444535 2021-10-25
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT00536939 2020-09-24
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT02613208 2020-02-17
Argo
Hoffmann-La Roche
Completed
NCT00394082 2019-11-25
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Celgene
Phase 2 Completed
NCT00394251 2019-11-25
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Celgene
Phase 2 Completed
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT01663727 2019-01-22
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00559845 2018-04-09
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01094184 2018-03-22
BATMAN
Hoffmann-La Roche
Phase 4 Completed
NCT01142778 2018-03-16
AVATAXHER
Hoffmann-La Roche
Phase 2 Completed
NCT02248571 2017-11-13
IMPROVE
iOMEDICO AG
Phase 4 Completed
NCT01186991 2017-01-20
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
Genentech, Inc.
Phase 2 Completed
NCT00960960 2016-12-15
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
Genentech, Inc.
Phase 1 Completed
NCT00774241 2016-11-02
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 4 Withdrawn
NCT00845910 2016-11-02
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00964704 2016-11-02
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Withdrawn
NCT01156961 2016-11-02
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
Hoffmann-La Roche
Phase 4 Withdrawn
NCT01254526 2016-11-02
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Genentech, Inc.
Phase 1 Completed
NCT00811135 2016-09-29
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00868634 2016-08-31
CARIN
iOMEDICO AG
Phase 3 Completed
NCT00717405 2016-08-02
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT01201265 2016-05-27
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00370552 2016-03-10
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
R-Pharm
Phase 2 Completed
NCT01215123 2016-02-22
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Hoffmann-La Roche
Completed
NCT01250379 2016-02-11
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Hoffmann-La Roche
Phase 3 Completed
NCT00333775 2016-01-27
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01256762 2016-01-26
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Geron Corporation
Phase 2 Completed
NCT00511459 2015-10-29
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Amgen
Phase 2 Completed
NCT00356681 2015-10-15
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
Amgen
Phase 2 Terminated
NCT00528567 2015-09-04
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00391092 2015-08-28
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT00448591 2015-05-25
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT00929240 2015-03-03
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00559754 2014-11-10
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
Hoffmann-La Roche
Phase 2 Completed